The utilization of PSMA PET is currently well established in both hormone-sensitive (HSPCa) and castrate-resistant (CRPCa) advanced prostate cancer; however, it is only recommended by guidelines as an expert opinion [4,5,12,13]. This evidence concerns the gene FOLH1 and prostate carcinoma.